OBJECTIVE: Evidence documenting management of incidental findings (IFs) from clinical genomic testing is limited. The aim of this study was to examine genetics specialists' perspectives regarding current and preferred disclosure of clinical genomic IFs. METHODS: 50 genetics specialists, including medical geneticists, laboratory professionals, genetic counselors, and nurses participated in structured telephone interviews. Data were analyzed using qualitative content analysis and descriptive statistics. RESULTS: Most specialists had encountered IFs, but definitions of IFs varied. They discussed challenges with informing patients about the prospect of IFs and disclosing IFs to patients. Causing psychological harm to patients was a concern. Participants were divided on whether IFs needed to be clinically significant and/or actionable in order to be disclosed to patients. Creating formal disclosure guidelines was considered useful, but only if they were flexible. Additional counseling, more interdisciplinary communication, maintaining contact with patients, and a centralized database to interpret IFs were also proposed. CONCLUSION: Genetics specialists offer insights into the challenges of defining IFs, knowing when and how to disclose them, and the potential need for flexible disclosure guidelines. PRACTICE IMPLICATIONS: Further discussion between practicing genetics specialists is needed to develop consensus on the development of best-practice guidelines for IF management.
OBJECTIVE: Evidence documenting management of incidental findings (IFs) from clinical genomic testing is limited. The aim of this study was to examine genetics specialists' perspectives regarding current and preferred disclosure of clinical genomic IFs. METHODS: 50 genetics specialists, including medical geneticists, laboratory professionals, genetic counselors, and nurses participated in structured telephone interviews. Data were analyzed using qualitative content analysis and descriptive statistics. RESULTS: Most specialists had encountered IFs, but definitions of IFs varied. They discussed challenges with informing patients about the prospect of IFs and disclosing IFs to patients. Causing psychological harm to patients was a concern. Participants were divided on whether IFs needed to be clinically significant and/or actionable in order to be disclosed to patients. Creating formal disclosure guidelines was considered useful, but only if they were flexible. Additional counseling, more interdisciplinary communication, maintaining contact with patients, and a centralized database to interpret IFs were also proposed. CONCLUSION: Genetics specialists offer insights into the challenges of defining IFs, knowing when and how to disclose them, and the potential need for flexible disclosure guidelines. PRACTICE IMPLICATIONS: Further discussion between practicing genetics specialists is needed to develop consensus on the development of best-practice guidelines for IF management.
Authors: Annelien L Bredenoord; Hester Y Kroes; Edwin Cuppen; Michael Parker; Johannes J M van Delden Journal: Trends Genet Date: 2010-12-27 Impact factor: 11.639
Authors: J Illes; M P Kirschen; E Edwards; P Bandettini; M K Cho; P J Ford; G H Glover; J Kulynych; R Macklin; D B Michael; S M Wolf; T Grabowski; B Seto Journal: Neurology Date: 2008-01-29 Impact factor: 9.910
Authors: K L Edwards; A A Lemke; S B Trinidad; S M Lewis; H Starks; M T Quinn Griffin; G L Wiesner Journal: Public Health Genomics Date: 2011-04-11 Impact factor: 2.000
Authors: Sato Ashida; Laura M Koehly; J Scott Roberts; Clara A Chen; Susan Hiraki; Robert C Green Journal: Eur J Hum Genet Date: 2010-07-28 Impact factor: 4.246
Authors: Debra S Brandt; Laura Shinkunas; Stephen L Hillis; Sandra E Daack-Hirsch; Martha Driessnack; Nancy R Downing; Megan F Liu; Lisa L Shah; Janet K Williams; Christian M Simon Journal: J Genet Couns Date: 2013-04-02 Impact factor: 2.537
Authors: Fook Yee Cheung; Lauren Clatch; Susan M Wolf; Ellen Wright Clayton; Frances Lawrenz Journal: J Law Med Ethics Date: 2020-03 Impact factor: 1.718
Authors: S Daack-Hirsch; M Driessnack; A Hanish; V A Johnson; L L Shah; C M Simon; J K Williams Journal: Clin Genet Date: 2013-05-03 Impact factor: 4.438